Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Travere Therapeutics Inc (NQ: TVTX ) 17.72 -0.75 (-4.06%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Travere Therapeutics Inc < Previous 1 2 ... 4 5 6 7 8 9 10 11 Next > 12 Health Care Stocks Moving In Monday's Intraday Session February 20, 2023 Via Benzinga Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy February 17, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Travere Therapeutics Announces FDA Accelerated Approval of FILSPARITM (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy February 17, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire The Latest Analyst Ratings for Travere Therapeutics January 30, 2023 Via Benzinga 4 Analysts Have This to Say About Travere Therapeutics December 05, 2022 Via Benzinga Where Travere Therapeutics Stands With Analysts December 05, 2022 Via Benzinga Recap: Travere Therapeutics Q3 Earnings October 27, 2022 Travere Therapeutics (NASDAQ:TVTX) reported its Q3 earnings results on Thursday, October 27, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Via Benzinga Travere Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results February 16, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 13, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present at Upcoming Investor Conferences February 08, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire The Nasdaq Is Rebounding: 2 Supercharged Growth Stocks to Buy in February February 01, 2023 These two growth stocks might deliver enormous gains for shareholders this month. Via The Motley Fool February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More January 31, 2023 The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... Via Benzinga Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 12, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Provides Corporate Update and 2023 Outlook January 09, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference January 03, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 14, 2022 From Travere Therapeutics, Inc. Via GlobeNewswire Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022 December 14, 2022 Via Benzinga Stocks That Hit 52-Week Lows On Monday December 12, 2022 Monday saw 196 companies set new 52-week lows. Via Benzinga Stocks That Hit 52-Week Lows On Tuesday November 22, 2022 During Tuesday's trading, 160 companies set new 52-week lows. Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For December 5, 2022 December 05, 2022 Via Benzinga Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 16, 2022 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics, the IgA Nephropathy Foundation, and NephCure Kidney International Partner to Launch RKD & Me, a Campaign to Raise Awareness of Rare Kidney Disease November 15, 2022 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present at Upcoming Investor Conferences November 09, 2022 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Earnings Perspective: Return On Capital Employed November 03, 2022 Benzinga Pro data, Travere Therapeutics (NASDAQ:TVTX) reported Q3 sales of $53.50 million. Earnings fell to a loss of $69.66 million, resulting in a 3.91% decrease from last quarter. Via Benzinga Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know November 01, 2022 October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the... Via Benzinga Travere Therapeutics Reports Third Quarter 2022 Financial Results October 27, 2022 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Announces Presentations and Posters at American Society of Nephrology Kidney Week 2022 October 26, 2022 Data support the Company’s lead investigational product candidate sparsentan From Travere Therapeutics, Inc. Via GlobeNewswire Earnings Scheduled For October 27, 2022 October 27, 2022 Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million. Via Benzinga Earnings Outlook For Travere Therapeutics October 26, 2022 Travere Therapeutics (NASDAQ:TVTX) is set to give its latest quarterly earnings report on Thursday, 2022-10-27. Here's what investors need to know before the announcement. Analysts estimate that... Via Benzinga Travere Therapeutics to Report Third Quarter 2022 Financial Results October 20, 2022 From Travere Therapeutics, Inc. Via GlobeNewswire < Previous 1 2 ... 4 5 6 7 8 9 10 11 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
